Shares of DelMar Pharmaceuticals Inc (NASDAQ:DMPI) ended Tuesday session in green amid volatile trading. The shares closed up +0.05 points or 1.16% at $4.13 with 10910 shares getting traded. Post opening the session at $4.04, the shares hit an intraday low of $4.04 and an intraday high of $4.15 and the price vacillated in this range throughout the day.
Market Cap/Outstanding Shares
The company has a market cap of $42.81 million and the number of outstanding shares have been calculated to be 10.42 million shares.
Performance weekly/monthly/quarterly/yearly in percentage (%)
The performance for the week is valued at 2.17%, resulting in a performance for the month at -20.93%. Therefore, the stated figure displays a quarterly performance of -34.48% with traded up 1.16% on 22 November, 2016 hitting $4.13.
EPS (Earning Per Share )
The EPS of DMPI is strolling at -0.81, measuring its EPS growth this year at -77.20%. As a result, the company has an EPS growth of -34.60% for the approaching year.
Beta factor is stands at 0.83 and Avg. true range is 0.34. Historically, the volatility of this stock is about 6.80% a week and 8.67% a month.
DelMar Pharmaceuticals Inc (DMPI) declared Corporate Update.
RECENT CORPORATE HIGHLIGHTS
DelMar raised gross proceeds of about $7.2 million in a private placement and our common stock began trading on the Nasdaq Capital Markets under the symbol “DMPI”;
DelMar confirmed that the Institutional Review Board (“IRB”) at the University of Texas MD Anderson Cancer Center (“MD Anderson”) approved our planned Phase II clinical study with VAL-083 in patients with GBM at first recurrence/progression;
DelMar stated promising data from our Phase I/II clinical trial of VAL-083 in refractory GBM at the American Society of Clinical Oncology (“ASCO”) annual meeting; supporting the potential for an improved survival benefit for bevacizumab-failed GBM patients treated with VAL-083 in comparison to current salvage chemotherapy;
DelMar declared the successful completion of an ‘End of Phase II’ meeting with the FDA and confirmed plans to advance VAL-083 into a pivotal Phase III clinical trial for GBM patients whose tumors have progressed following treatment with bevacizumab;
DelMar reached a collaborative research agreement with Accurexa, Inc. to explore local delivery of VAL-083 as a potential combination therapy for the treatment of brain tumors;